雄激素受体对三阴性乳腺癌新辅助治疗的影响：一项系统综述和荟萃分析。

Q2 Medicine Asian Pacific Journal of Cancer Prevention Pub Date : 2024-12-01 DOI:10.31557/APJCP.2024.25.12.4115

Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono

{"title":"雄激素受体对三阴性乳腺癌新辅助治疗的影响：一项系统综述和荟萃分析。","authors":"Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono","doi":"10.31557/APJCP.2024.25.12.4115","DOIUrl":null,"url":null,"abstract":"Objective: Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), the progesterone receptor (PR), or the human epidermal growth factor receptor 2 (HER2). TNBC has limited treatment targets, including the androgen receptor (AR). However, the therapeutic strategies-based AR expression in TNBC remains uncertain. The aim of this study is to compare the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus receptor-negative patients.Methods: A systematic search was performed through databases to search for cohort studies that compared the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus TNBC receptor-negative patients. The Mantel-Haenzel and Inverse Variance methods obtained a fixed-effects model of pooled odds or hazard ratios for the primary outcomes.Results: Fifteen cohort studies, including 2,713 patients with TNBC, were assessed. The effect of neoadjuvant chemotherapy is less superior on AR+ patients than AR- (OR = 0.60, p = 0.02). For survival outcomes, the AR+ subtype is associated with better 3-year DFS (HR = 0.93, p = 0.69) and 3-year OS (HR = 0.71, p = 0.20) compared with AR-. The statistical value is insignificant.Conclusion: The prognostic value of AR expression in TNBC is not fully understood, which is an inconclusive result.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"25 12","pages":"4115-4122"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis.\",\"authors\":\"Ottofianus Alvedo Hewick Kalangi, Tioky Sutjonong, Erica A Indrawan, Hayyan Ageng Pratama, Yohana Azhar, Asdi Wihandono\",\"doi\":\"10.31557/APJCP.2024.25.12.4115\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), the progesterone receptor (PR), or the human epidermal growth factor receptor 2 (HER2). TNBC has limited treatment targets, including the androgen receptor (AR). However, the therapeutic strategies-based AR expression in TNBC remains uncertain. The aim of this study is to compare the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus receptor-negative patients.Methods: A systematic search was performed through databases to search for cohort studies that compared the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus TNBC receptor-negative patients. The Mantel-Haenzel and Inverse Variance methods obtained a fixed-effects model of pooled odds or hazard ratios for the primary outcomes.Results: Fifteen cohort studies, including 2,713 patients with TNBC, were assessed. The effect of neoadjuvant chemotherapy is less superior on AR+ patients than AR- (OR = 0.60, p = 0.02). For survival outcomes, the AR+ subtype is associated with better 3-year DFS (HR = 0.93, p = 0.69) and 3-year OS (HR = 0.71, p = 0.20) compared with AR-. The statistical value is insignificant.Conclusion: The prognostic value of AR expression in TNBC is not fully understood, which is an inconclusive result.\",\"PeriodicalId\":55451,\"journal\":{\"name\":\"Asian Pacific Journal of Cancer Prevention\",\"volume\":\"25 12\",\"pages\":\"4115-4122\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Pacific Journal of Cancer Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31557/APJCP.2024.25.12.4115\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2024.25.12.4115","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的：三阴性乳腺癌（triple negative breast cancer， TNBC）是一种不表达雌激素受体（ER）、孕激素受体（PR）或人表皮生长因子受体2 （HER2）的乳腺癌。TNBC的治疗靶点有限，包括雄激素受体（AR）。然而，在TNBC中基于AR表达的治疗策略仍然不确定。本研究的目的是比较新辅助治疗对TNBC雄激素受体阳性和受体阴性患者的影响。方法：通过数据库进行系统搜索，寻找比较新辅助治疗对TNBC雄激素受体阳性和TNBC受体阴性患者效果的队列研究。Mantel-Haenzel和逆方差方法获得了主要结果的合并几率或风险比的固定效应模型。结果：15项队列研究，包括2713例TNBC患者，被评估。AR+患者的新辅助化疗效果不如AR-患者（OR = 0.60, p = 0.02）。对于生存结果，AR+亚型与AR-相比具有更好的3年DFS （HR = 0.93, p = 0.69）和3年OS （HR = 0.71, p = 0.20）。统计值不显著。结论：AR表达在TNBC中的预后价值尚不完全清楚，这是一个不确定的结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Effect of Androgen receptors in Triple-Negative Breast Cancer Given Neoadjuvant Therapy: A Systematic Review and Meta-Analysis.

Objective: Triple-negative breast cancer (TNBC) is a type of breast cancer that does not express the estrogen receptor (ER), the progesterone receptor (PR), or the human epidermal growth factor receptor 2 (HER2). TNBC has limited treatment targets, including the androgen receptor (AR). However, the therapeutic strategies-based AR expression in TNBC remains uncertain. The aim of this study is to compare the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus receptor-negative patients.

Methods: A systematic search was performed through databases to search for cohort studies that compared the effect of neoadjuvant treatment on TNBC androgen receptor-positive versus TNBC receptor-negative patients. The Mantel-Haenzel and Inverse Variance methods obtained a fixed-effects model of pooled odds or hazard ratios for the primary outcomes.

Results: Fifteen cohort studies, including 2,713 patients with TNBC, were assessed. The effect of neoadjuvant chemotherapy is less superior on AR+ patients than AR- (OR = 0.60, p = 0.02). For survival outcomes, the AR+ subtype is associated with better 3-year DFS (HR = 0.93, p = 0.69) and 3-year OS (HR = 0.71, p = 0.20) compared with AR-. The statistical value is insignificant.

Conclusion: The prognostic value of AR expression in TNBC is not fully understood, which is an inconclusive result.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.